13F Holdings
中文EN

OABI OmniAb, Inc.

Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1846253 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY90.6%
TTM net income YoY31.7%
TTM EPS YoY42.4%
Revenue 3-yr CAGR-14.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-115.9%
Net margin-108.1%
FCF margin5.9%
EBITDA margin-64.2%

Returns

ROE-16.5%
ROA-14.5%
ROIC (approx.)-15.5%
Asset turnover0.13x

Leverage & solvency

Liabilities / assets14.4%
Debt / equity0.00x
Current ratio4.21x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.06x
Accruals ratio-15.4%
Payout ratio—
Capex / revenue0.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$18.67M$26.39M$34.16M$59.08M$34.75M
R&D expense$47.75M$55.11M$56.52M$48.36M$39.23M
SG&A expense$29.21M$30.74M$33.31M$24.90M$16.95M
Operating income-$68.97M-$74.50M-$69.42M-$26.65M-$35.61M
Interest expense———$0$7,000
Pretax income-$66.29M-$71.41M-$64.36M-$26.06M-$34.35M
Income tax-$1.51M-$9.38M-$13.74M-$3.73M-$7.31M
Net income-$64.78M-$62.03M-$50.62M-$22.33M-$27.04M
EBITDA-$47.22M-$50.92M-$49.92M-$8.40M-$19.36M
EPS (basic)-0.57-0.61-0.51-0.26-0.33
EPS (diluted)-0.57-0.61-0.51-0.26-0.33
Weighted avg. shares (diluted)113.64M102.36M99.68M85.32M82.61M
Balance sheet
Cash & equivalents$25.52M$28.16M$16.92M$33.84M$0
Short-term investments$28.50M$31.84M$70.62M$54.88M$0
Receivables$7.39M$5.27M$3.84M$30.29M$21.14M
Inventory$823,000$48,000———
Current assets$65.34M$68.14M$94.90M$124.95M$22.54M
PP&E, net$9.43M$15.49M$18.25M$19.98M$6.79M
Goodwill$83.98M$83.98M$83.98M$83.98M$83.98M
Intangibles$125.15M$138.06M$155.47M$167.24M$176.32M
Total assets$300.91M$325.56M$375.23M$421.21M$304.46M
Current liabilities$16.25M$15.09M$23.12M$26.02M$20.58M
Total liabilities$33.89M$37.94M$60.64M$79.84M$70.16M
Shareholders' equity$267.03M$287.62M$314.58M$341.37M$234.31M
Shares outstanding144.31M121.60M116.86M115.22M0
Cash flow statement
Operating cash flow-$36.45M-$39.66M$2.35M-$3.59M-$5.67M
Capital expenditure$565,000$1.88M$1.64M$17.17M$4.07M
Free cash flow-$37.02M-$41.54M$703,000-$20.75M-$9.74M
Investing cash flow$6.47M$37.88M-$18.38M-$73.31M-$4.03M
Financing cash flow$27.91M$13.02M-$892,000$110.74M$9.70M
Depreciation & amortization$21.75M$23.58M$19.50M$18.25M$16.25M
Stock-based compensation$15.82M$21.50M$24.82M$18.32M$15.06M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.